Effectiveness of these novel drugs may likely be extended to unresectable or metastatic SDH-deficient renal cell carcinomas, gastrointestinal stroma tumors, thyroid, and pancreatic neuroendocrine tumors, or other conditions exhibiting disturbed SUCNR1-signaling due to hypoxia or hyperglycemia. The gene discussed is SDHB; the disease is Hyperglycemia.